| G |
|
G20210A prothrombin gene mutation appears as the most important inherited prothrombotic risk factor in ‘idiopathic’ portal vein thrombosis
|
| Maakaroun A., Delahousse B., Fimbel B., D'Alteroche L., Gruel Y. |
| |
|
G20210A prothrombin mutation and allele 4G of gene PAI-1 in deep vein thrombosis
|
| Fenu L., Cauli C., Pisu G., Marongiu F., Barcellona D. |
| |
|
G20210A prothrombin mutation and factor V Leiden (G1691A) to address local health policy
|
| Barcellona D., Fenu L., Cauli C., Marongiu F. |
| |
|
Gas6
|
| García De Frutos P. |
| |
|
Gene array transcript profiling of human endothelial cells identifies pathways regulated by Drotregocin alfa (activated)
|
| Brueckmann M., Lang S., Weiler H. M., Liebe V., Hoffmann U., Borggrefe M., Haase K. K., Huhle G. |
| |
|
Gene expression analysis in platelets: use of a PCR-based RNA amplification technique for generating suitable amounts of cDNA
|
| Rox J., Mueller J., Otte J., Madlener K., Poetzsch B. |
| |
|
Gene targeting of platelets
|
| Poncz M. |
| |
|
Gene therapy for haemophilias
|
| Vandendriessche T., Collen D., Chuah M. K. L. |
| |
|
Gene therapy for hemophilia A with high-capacity adenoviral vectors: preclinical evaluation in hemophilic mice and dogs
|
| Vandendriessche T., Schiedner G., Thorrez L., Brown B., Lillicrap D., Van Rooijen N., Collen D., Kochanek S., Chuah M. |
| |
|
Gene transfer of naked plasmid DNA encoding VEGF121 leads to revascularization of ischemic tissue in animal models of vascular diseases
|
| Garcia Ojalvo A., Seralena A., Vispo N. S., Vazquez R., Montequin J. F., Aldama A., Gonzalez N., Guevara L., Batista J. F., Coca M., Silva R., Puchades Y., Ali A., Lopez-Saura P., Sorell L. T., Alfonso M. A., Simon R., Seuc A., Chaos N., Creach O., Gonzalez R., Peña Y., Perera A., Garcia-Osuna T., Dominguez H., Reyes J. L., Herrera L. |
| |
|
Gene transfer of naked plasmid DNA encoding VEGF121 leads to revascularization of ischemic tissue in animal models of vascular diseases
|
| Ojalvo A., Seralena A., Vispo N. S., Silva R., Vázquez R., Puchades Y., Alí A., Lopez-Saura P., Montequín J. F., Sorell L. T., Aldama A., Alfonso M. A., Simón R., Seuc A., González N., Guevara L., Chaos N., Creach O., González R., Batista J. F., Peña Y., Coca M., Perera A., García-Osuna T., Domínguez H., Reyes J. L., Herrera L. |
| |
|
Generation and characterization of a highly stable form of activated TAFI
|
| Marx P. F., Havik S. R., Bouma B. N., Meijers J. C. M. |
| |
|
Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lanka ancestry: in vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X
|
| Isshiki I., Moriki T., Murata M., Ishihara H., Uchida T., Shibano T., Ashida S., Tabone M. O., Van Dreden P., Ikeda Y., Favier R. |
| |
|
Genetic and physical mapping of the platelet disorder in the fawn-hooded hypertensive rat
|
| Datta Y. H., Wu F. C., Dumas P. C., Rangel-Filho A., Datta M. W., Ning G., Jacob H. J. |
| |
|
Genetic basis of inhibitor development
|
| Oldenburg J. |
| |
|
Genetic coregulation of C4b-binding protein (C4BP) and free Protein S plasma levels: a link between complement and hemostasis
|
| Esparza-Gordillo J., Soria J.M., Buil A., Martinez-Marchan E., Martinez-Sanchez E., Souto J.C., Almasy L., Blangero J., Rodriguez De Codoba S., Fontcuberta J. |
| |
|
Genetic dissection of thrombin-activatable fibrinolysis inhibitor (TAFI)
|
| Buil A., Soria J. M., Souto J. C., Borell M., Almasy L., Lathrop M., Vallve C., Mateo J., Ortin R., Blangero J., Fontcuberta J. |
| |
|
Genetic features of thrombophilia in pediatric patients with migraine
|
| Tadtaeva Z. G., Katsadze Y. I. L. |
| |
|
Genetic mechanisms underlying the clinical manifestation of hemophilia A in females
|
| Pavlova A., Schroeder J., Ivaskevicius V., Brackmann H. H., Seifried E., Oldenburg J. |
| |
|
Genetic modifications that increase factor VIII secretion in vitro and in vivo
|
| Pipe S. W., Miao H. Z., Sirachainan N., Cunningham M. A., Kaufman R. J. |
| |
|
Genetic polymorphisms and the risk of development of ischemic stroke. Result of a case control study
|
| Toulon P., Zuber M., Mas J. L. |
| |
|
Genetic profiling of 20 patients with FVII deficiency by dHPLC and sequence analysis: detection of 7 novel mutations
|
| Geisen C., Freyaldenhoven B., Söhngen D., Schulz A., Daugela L., Watzka M., Pavlova A., Ivaskevicius V., Wielckens K., Seifried E., Oldenburg J. |
| |
|
Genetic risk factors in patients with myocardial infarction and correlation with echocardiographic study
|
| Paraskevopouloy P., Likousi S., Sotirelos K., Antonatos D., Tsigkas D., Katelani M. |
| |
|
Genetic susceptibility of venous thromboembolism: role of the procoagulant, anticoagulant, fibrinolytic, and acute inflammation pathways
|
| Heit J. A., Petterson T. M., Ballman K. V., de Andrade M., Burke J. P., Melton III L. J. |
| |
|
Genetic thrombophilia in Romanian women with pregnancy loss and pre-eclampsia
|
| Procopciuc L., Jebeleanu G. |
| |
|
Genetic variability of von Willebrand factor and coronary heart disease: the Rotterdam Study
|
| Leebeek F. W. G., Van Der Meer I. M., Brouwers G. J., Gomez-Garcia E. B., Van Der Kuip D. A. M., Hofman A., Witteman J. C. M. |
| |
|
Genetic variants of CYP2C9 cytochrome do not account for high intraindividual variability of patients in their response to oral anti-coagulants (OA): a collaborative controlled study
|
| Palareti G., Legnani G., Poli D., Prisco D., Bernadi F. |
| |
|
Genetic variation at the human thrombomodulin promoter locus and prognosis after acute coronary syndrome
|
| Öhlin A., Holm J., Hillarp A. |
| |
|
Genetic variations of the extra-large stimulatory G protein a-subunit and risk of thrombotic and hemorrhagic disorders
|
| González-Conejero R., Guerrero J. A., Corral J., Iniesta J. A., Rivera J., Vicente V. |
| |
|
Genetically defined protein S (PS) deficiency is associated with venous thrombosis
|
| Biguzzi E., Fontana G., Castaman G., Razzari C., Margaglione M., Prisco D., Castori L., Brancaccio V., Bucciarelli P., Faioni E. M., on behalf of PROSIT, Protein S Italian Team, Italy |
| |
|
Genetics
|
| Aiach M. |
| |
|
Genetics of atherothrombotic disorders: a clinical perspective
|
| Grant P. |
| |
|
Genetics of fibrin clot structure and interactions with factor XIII: a twin study
|
| Dunn E., Ariens R. A. S., De Lange M., Snieder H., Spector T. D., Grant P. J. |
| |
|
Genomic structure, organization and promoter analysis of the human F11 receptor (F11R) (junctional adhesion molecule-1, JAM-1)
|
| Sobocki T., Sobocka M. B., Babinska A., Ehrlich Y. H., Banerjee P., Kornecki E., Rushbrook J. I. |
| |
|
Geographic distribution of asymptomatic constitutional macro thrombocytopenia in Indian subcontinent
|
| Harris V. K., Woodfield D. G., Sukesh C. N., Paul C., Ankit B. |
| |
|
GH9001, a novel anti-thrombotic agent, is more effective than low-molecular-weight heparin, fondaparinux, or hirudin in rabbit models
|
| Weitz J., Klement P., Liao P., Stafford A., Fredenburgh J., Johansen K., Hirsh J. |
| |
|
Gla-domain mutated human protein C demonstrating enhanced inactivation of both factor Va and factor VIIIa
|
| Sun Y., Norstrom E., Dahlbäck B. |
| |
|
Glanzmann thrombasthenia: a study of two Portuguese families and identification of a new homozygous C insertion in exon 10 of the GPIIIa
|
| Corbillón L., Lima M., Morais S., Teixeira M. A., Campos M., Justiça B., Breillat C., Combrié R., Bourre F., Nurden A. T. |
| |
|
Glanzmanns thrombasthenia in Indians – how different it is from other ethnic groups
|
| Ghosh K., Nair S., Mohanty D., Shetty S. |
| |
|
Global hemostatic tests, protein C and anti-thrombin in the intensive care unit setting; correlations and ability to predict outcome
|
| Nilsson G., Astermark J., Vernersson E., Berntorp E. |
| |
|
Globotriasylceramide (Gb3) and blood-borne tissue factor (TF) colocalize with platelets during platelet adhesion/aggregation onto a collagen-coated surface exposed to flowing blood
|
| Grabowski E. F., Nestoridi E., Schumann S. A., Kushak R. I., Ingelfinger J. R. |
| |
|
Glycoprotein Ib and integrin a IIbb 3 contribute to GPVI-dependent vWF-collagen induced thrombus formation under flow
|
| Kuijpers M. J. E., Oury C., Schulte V., Feijge M. A. H., Hoylaerts M. F., Lindhout T., Nieswandt B., Heemskerk J. W. M. |
| |
|
Glycoprotein Ib-mediated platelet activation: a signaling pathway evoked by thrombin
|
| Adam F., Guillin M. C., Jandrot-Perrus M. |
| |
|
Glycoprotein IIb/IIIa complex is the target in mirtazapine-induced immune thrombocytopenia
|
| Sahud M. |
| |
|
Glycoprotein IX Asn45Ser: an ancestral mutation causing Bernard–Soulier syndrome in Europeans?
|
| Liang H. P., Morel-Kopp M-C., Michaelides K., Tuddenham E. G. D., Vanhoorelbeke K., Clemetson K. J., Ward C. M. |
| |
|
Glycosyl Phosphatidylinositol (GPI)-anchored protein(s) are required for cell surface expression of tissue factor pathway inhibitor (TFPI)
|
| Cunningham A. C., Mansbach C. M., Mast A. E. |
| |
|
Glycoxidation products and S100 calgranulin binding to RAGE induce tissue factor production
|
| Boulogne A., Wautier M. P., Gane P., Boulanger E., Wautier J. L. |
| |
|
Good efficacy of low dosing regimen of a FVIII/vWF concentrate in patients with von Willebrand disease
|
| Vorlova Z., Habart D., Salaj P. |
| |
|
GP IIb-IIIa antagonists and thrombin generation
|
| Siegemund A., Siegemund T., Petros S., Scholz U., Engelmann L. |
| |
|
GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention
|
| Michelson A. D., Krueger L. A., Furman M. I., Barnard M. R., Fox M. L., Frelinger A. L. |
| |
|
GPRP interferes with FXIIIa in localization to immobilized Fibrin(ogen) and with platelet deposition in different thrombosis models
|
| Harsfalvi J., Debreceni I., Meiring M., Deckmyn H. |
| |
|
GPVI- and GPIb/V/IX-induce tyrosine phosphorylation at Syk and PLCg2 at distinct sites
|
| Suzuki-Inoue K., Wilde J. I., Andrews R. K., Siraganian R. P., Sekiya F., Rhee S. G., Watson S. P. |
| |
|
Gramicetin: a new agonist that activates platelets via glycoprotein Ib ligation
|
| Wu W. B., Huang T. F. |
| |
|
Granulocyte colony-stimulating factor exerts a pro-inflammatory effect on endothelial cells through activation of p38 MAPK
|
| Fuste B., Diaz-Ricart M., Mazzara R., Escolar G., Ordinas A. |
| |
|
GTT: A comprehensive in vitro haemostasis test, assessing platelet function, coagulation and thrombolytic activity from a single native blood sample
|
| Yamamoto J., Yamashita T., Ikarugi H., Taka T., Hashimoto M., Ishii H., Watanabe S., Kovacs I.B. |
| |
|
Guidelines on management of nontherapeutic INRs: are really easy to apply in daily practice?
|
| Pattacini C., Tagliaferri A., Lombardi M. R., Quintvilla R., Manotti C. |
| |
